ArticleIDCases2025
Ceftriaxone induced pancreatitis: A case report with review of literature.
Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ceftriaxone is a widely used third-generation cephalosporin that is generally well tolerated. However, rare complications such as acute pancreatitis may occur, potentially due to the precipitation of ceftriaxone in the bile. Case Observation: We report the case of a 62-year-old man diagnosed with a urinary tract infection and treated with intravenous ceftriaxone. On the eighth day of treatment, the patient developed dyspepsia, nausea, epigastric pain, and fever. Laboratory tests revealed elevated levels of lipase and amylase, and abdominal computed tomography confirmed a diagnosis of acute pancreatitis. Suspecting a ceftriaxone-induced adverse reaction, the antibiotic was discontinued. Within 72 hours, laboratory values normalized and clinical symptoms resolved. Conclusion: Although rare, clinicians should consider ceftriaxone as a potential cause of acute pancreatitis, especially when no other causes are evident. Prompt discontinuation of the drug typically results in rapid clinical and biochemical improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.